ContraFect Corp (NASDAQ:CFRX)’s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.45 and traded as high as $0.39. ContraFect shares last traded at $0.37, with a volume of 4,327 shares trading hands.
CFRX has been the subject of several recent analyst reports. Maxim Group initiated coverage on ContraFect in a research report on Tuesday, June 11th. They set a “buy” rating for the company. Chardan Capital restated a “buy” rating and set a $1.50 target price on shares of ContraFect in a research report on Wednesday, May 15th. Finally, ValuEngine upgraded ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
The company has a debt-to-equity ratio of 0.37, a current ratio of 4.15 and a quick ratio of 4.15. The stock has a market cap of $30.18 million, a PE ratio of -1.03 and a beta of 0.07. The business has a fifty day moving average of $0.45 and a 200-day moving average of $0.46.
ContraFect Company Profile (NASDAQ:CFRX)
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Further Reading: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.